TIMM17B

Across TCGA pan-cancer cohorts, TIMM17B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TIMM17B data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TIMM17B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TIMM17B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where TIMM17B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.527	.018	4	view →
PDAC	OS	Tertile	All	0.624	0.425	.024	4	view →
LSCC	OS	Median	All	1.000	0.924	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TIMM17B–CCRCC (DFS)

Open the CCRCC breakdown →